Revolution Medicines/$RVMD
1D1W1MYTD1Y5YMAX
Capital at risk
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
- Ticker
- $RVMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 883
- Headquarters
- Redwood City, United States
- Website
- www.revmed.com
RVMD Metrics
BasicAdvanced
$44B
-
-$8.92
1.41
-
Price and volume
Market cap
$44B
Beta
1.41
52-week high
$224.31
52-week low
$45.61
Average daily volume
2.1M
Financial strength
Current ratio
11.378
Quick ratio
11.122
Long term debt to equity
0.45
Total debt to equity
0.457
Interest coverage (TTM)
-27.42%
Profitability
EBITDA (TTM)
-1,618.188
Management effectiveness
Return on assets (TTM)
-30.12%
Return on equity (TTM)
-79.09%
Valuation
Price to book
16.92
Price to tangible book (TTM)
17.39
Price to free cash flow (TTM)
-33.121
Free cash flow yield (TTM)
-3.02%
Free cash flow per share (TTM)
-6.216
Growth
Earnings per share change (TTM)
97.14%
3-year earnings per share growth (CAGR)
41.44%
What the Analysts think about RVMD
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
Analyst projections of the future price of Revolution Medicines stock.
Bulls say / Bears say
In Phase 3 RASolute 302, daraxonrasib improved median overall survival to 13.2 months from 6.7 months with chemotherapy, with no new safety signals. The FDA has accepted the pancreatic-cancer filing, giving Revolution a credible route to its first commercial launch. (Revolution Medicines, Revolution Medicines)
Daraxonrasib showed meaningful activity in previously treated RAS-mutant lung cancer: a 42% response rate and 89% disease-control rate in a 38-patient subgroup, with median progression-free survival of 8.3 months. These results have supported the ongoing global Phase 3 RASolve 301 trial against docetaxel. (GlobeNewswire)
Revolution ended June with $3.9 billion in cash, cash equivalents and marketable securities, plus up to $1.5 billion of further committed Royalty Pharma capital subject to milestones. That gives it substantial funding to run several Phase 3 programmes and build commercial infrastructure without an immediate financing need. (Revolution Medicines)
The lung-cancer safety profile still carries material execution risk: across the broader study, 54% of patients had a grade 3 or higher adverse event and 30% had a grade 3 or higher treatment-related event. Four grade 5 events occurred, although investigators did not classify them as treatment-related, and toxicity increased at the higher dose. (OncoDaily, GlobeNewswire)
Revolution remains highly cash-burning: it reported a $644.4 million second-quarter net loss, while 2026 operating expenses are expected to reach $2.1 billion to $2.2 billion. The April fund-raising strengthened liquidity but included common shares, so continued spending could bring further dilution before product revenue is established. (Revolution Medicines, Revolution Medicines)
The shares had risen 178% by late August after the pancreatic-cancer data, while the bull case still relies on an estimated $11.5 billion peak-sales opportunity and approvals beyond the initial indication. That leaves little room for a weak launch, payer resistance or disappointing Phase 3 results in earlier-line disease. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 24 Sept 2026.
RVMD Financial Performance
Revenues and expenses
RVMD Earnings Performance
Company profitability
Upcoming events
No upcoming events
RVMD News
AllArticlesVideos
Funds containing RVMD
AllUSDGBPEUR
Fund name | Fund size | $RVMD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 2.88% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 2.88% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.35% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.10% |
iShares MSCI USA ESG Enhanced€OM3L | €16B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.